Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by PATRICIA J EIFEL and ANN H KLOPP.
PATRICIA J EIFEL
Connection Strength
8.039
ANN H KLOPP
  1. IMRT all the way. Int J Radiat Oncol Biol Phys. 2019 11 15; 105(4):692-693.
    View in: PubMed
    Score: 0.705
  2. In reply to Keenan et al. Anatomic principles as the basis of target volume definition. Radiother Oncol. 2019 07; 136:198-199.
    View in: PubMed
    Score: 0.652
  3. Pilot study of a computed tomography-compatible shielded intracavitary brachytherapy applicator for treatment of cervical cancer. Pract Radiat Oncol. 2013 Apr-Jun; 3(2):115-23.
    View in: PubMed
    Score: 0.419
  4. Biological predictors of cervical cancer response to radiation therapy. Semin Radiat Oncol. 2012 Apr; 22(2):143-50.
    View in: PubMed
    Score: 0.416
  5. Chemoradiotherapy for cervical cancer in 2010. Curr Oncol Rep. 2011 Feb; 13(1):77-85.
    View in: PubMed
    Score: 0.384
  6. Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation. Gynecol Oncol. 2009 Oct; 115(1):6-11.
    View in: PubMed
    Score: 0.345
  7. Gene expression profiling in cervical cancer: state of the art and future directions. Cancer J. 2006 May-Jun; 12(3):170-4.
    View in: PubMed
    Score: 0.276
  8. Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring. Cancer Cell. 2023 11 13; 41(11):1945-1962.e11.
    View in: PubMed
    Score: 0.232
  9. Circulating neutrophils and tumor-associated myeloid cells function as a powerful biomarker for response to chemoradiation in locally advanced cervical cancer. Clin Transl Radiat Oncol. 2023 Mar; 39:100578.
    View in: PubMed
    Score: 0.219
  10. Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers. Cancer Immunol Res. 2022 02; 10(2):259-271.
    View in: PubMed
    Score: 0.205
  11. Long-term survival following definitive radiation therapy for recurrence or oligometastases in gynecological malignancies: A landmark analysis. Gynecol Oncol. 2022 03; 164(3):550-557.
    View in: PubMed
    Score: 0.204
  12. Clinical utility and value contribution of an MRI-positive line marker for image-guided brachytherapy in gynecologic malignancies. Brachytherapy. 2020 May - Jun; 19(3):305-315.
    View in: PubMed
    Score: 0.181
  13. Microbial Diversity and Composition Is Associated with Patient-Reported Toxicity during Chemoradiation Therapy for Cervical Cancer. Int J Radiat Oncol Biol Phys. 2020 05 01; 107(1):163-171.
    View in: PubMed
    Score: 0.179
  14. Developing an intraoperative 3T MRI-guided brachytherapy program within a diagnostic imaging suite: Methods, process workflow, and value-based analysis. Brachytherapy. 2020 Jul - Aug; 19(4):427-437.
    View in: PubMed
    Score: 0.177
  15. Adjuvant combined-modality therapy for stage IIIC endometrioid and non-endometrioid endometrial cancer. Gynecol Oncol. 2019 07; 154(1):22-28.
    View in: PubMed
    Score: 0.170
  16. Kinetics of Intratumoral Immune Cell Activation During Chemoradiation for Cervical Cancer. Int J Radiat Oncol Biol Phys. 2018 11 01; 102(3):593-600.
    View in: PubMed
    Score: 0.161
  17. Effectiveness of definitive radiotherapy for squamous cell carcinoma of the vulva with gross inguinal lymphadenopathy. Gynecol Oncol. 2018 03; 148(3):474-479.
    View in: PubMed
    Score: 0.155
  18. Role of Radiation Therapy in the Multidisciplinary Management of Uterine Carcinosarcoma. Int J Gynecol Cancer. 2018 01; 28(1):114-121.
    View in: PubMed
    Score: 0.155
  19. Outcomes and patterns of relapse after definitive radiation therapy for oligometastatic cervical cancer. Gynecol Oncol. 2018 01; 148(1):132-138.
    View in: PubMed
    Score: 0.153
  20. In Reply to Mazeron et?al. Int J Radiat Oncol Biol Phys. 2017 03 01; 97(3):639.
    View in: PubMed
    Score: 0.146
  21. Impact of treatment year on survival and adverse effects in patients with cervical cancer and paraortic lymph node metastases treated with definitive extended-field radiation therapy. Pract Radiat Oncol. 2017 May - Jun; 7(3):e165-e173.
    View in: PubMed
    Score: 0.141
  22. Comparison of Computed Tomography- and Magnetic Resonance Imaging-based Clinical Target Volume Contours at Brachytherapy for?Cervical Cancer. Int J Radiat Oncol Biol Phys. 2016 11 15; 96(4):793-800.
    View in: PubMed
    Score: 0.140
  23. Management of nodal recurrences of endometrial cancer with IMRT. Gynecol Oncol. 2015 Oct; 139(1):40-6.
    View in: PubMed
    Score: 0.131
  24. Optimizing packing contrast for MRI-based intracavitary brachytherapy planning for cervical cancer. Brachytherapy. 2015 May-Jun; 14(3):385-9.
    View in: PubMed
    Score: 0.126
  25. Survival outcomes for patients with stage IVB vulvar cancer with grossly positive pelvic lymph nodes: time to reconsider the FIGO staging system? Gynecol Oncol. 2015 Feb; 136(2):269-73.
    View in: PubMed
    Score: 0.125
  26. Morbid obesity as an independent risk factor for disease-specific mortality in women with cervical cancer. Obstet Gynecol. 2014 Dec; 124(6):1098-1104.
    View in: PubMed
    Score: 0.125
  27. Relationship between low hemoglobin levels and outcomes after treatment with radiation or chemoradiation in patients with cervical cancer: has the impact of anemia been overstated? Int J Radiat Oncol Biol Phys. 2015 Jan 01; 91(1):196-205.
    View in: PubMed
    Score: 0.124
  28. Dosimetric predictors of duodenal toxicity after intensity modulated radiation therapy for treatment of the para-aortic nodes in gynecologic cancer. Int J Radiat Oncol Biol Phys. 2014 Feb 01; 88(2):357-62.
    View in: PubMed
    Score: 0.118
  29. Variable impact of intracavitary brachytherapy fractionation schedule on?biologically effective dose to organs at risk in patients with cervical?cancer. Brachytherapy. 2014 May-Jun; 13(3):240-9.
    View in: PubMed
    Score: 0.116
  30. Involved-field radiation therapy for locoregionally recurrent ovarian cancer. Gynecol Oncol. 2013 Aug; 130(2):300-5.
    View in: PubMed
    Score: 0.112
  31. Galectin-7 levels predict radiation response in squamous cell carcinoma of the cervix. Gynecol Oncol. 2013 Dec; 131(3):645-9.
    View in: PubMed
    Score: 0.112
  32. Anatomic distribution of fluorodeoxyglucose-avid para-aortic lymph nodes in patients with cervical cancer. Int J Radiat Oncol Biol Phys. 2013 Mar 15; 85(4):1045-50.
    View in: PubMed
    Score: 0.110
  33. Intensity modulated radiation therapy for definitive treatment of paraortic relapse in patients with endometrial cancer. Pract Radiat Oncol. 2013 Jan-Mar; 3(1):e21-e28.
    View in: PubMed
    Score: 0.105
  34. Anatomic distribution of [(18)F] fluorodeoxyglucose-avid lymph nodes in patients with cervical cancer. Pract Radiat Oncol. 2013 Jan-Mar; 3(1):45-53.
    View in: PubMed
    Score: 0.104
  35. Gene expression changes in cervical squamous cell carcinoma after initiation of chemoradiation and correlation with clinical outcome. Int J Radiat Oncol Biol Phys. 2008 May 01; 71(1):226-36.
    View in: PubMed
    Score: 0.079
  36. The Value of Patient-Reported Outcomes to Predict Symptom Burden and Health-Related Quality of Life After Chemoradiation for Cervical Cancer: A Prospective Study. Pract Radiat Oncol. 2024 Sep-Oct; 14(5):e353-e361.
    View in: PubMed
    Score: 0.060
  37. Exploratory analysis of the cervix tumoral HPV antigen-specific T-cell repertoire during chemoradiation and after brachytherapy. Brachytherapy. 2024 Mar-Apr; 23(2):123-135.
    View in: PubMed
    Score: 0.059
  38. Management and long-term clinical outcomes of patients with stage IVA cervical cancer with bladder involvement. Gynecol Oncol. 2024 01; 180:24-34.
    View in: PubMed
    Score: 0.058
  39. Patient Reported Outcomes for Women Undergoing Definitive Chemoradiation for Gynecologic Cancer: A Prospective Clinical Trial. Pract Radiat Oncol. 2023 Nov-Dec; 13(6):e538-e546.
    View in: PubMed
    Score: 0.057
  40. Metagenomes of rectal swabs in larger, advanced stage cervical cancers have enhanced mucus degrading functionalities and distinct taxonomic structure. BMC Cancer. 2022 Sep 01; 22(1):945.
    View in: PubMed
    Score: 0.054
  41. Longitudinal Changes in Bone Mineral Measurements Inside and Outside Radiation Fields Used for Cervical Cancer Treatment. Pract Radiat Oncol. 2022 Sep-Oct; 12(5):e423-e433.
    View in: PubMed
    Score: 0.052
  42. Use of Specific Duodenal Dose Constraints During Treatment Planning Reduces Toxicity After Definitive Paraaortic Radiation Therapy for Cervical Cancer. Pract Radiat Oncol. 2022 May-Jun; 12(3):e207-e215.
    View in: PubMed
    Score: 0.051
  43. A prospective study of the adaptive changes in the gut microbiome during standard-of-care chemoradiotherapy for gynecologic cancers. PLoS One. 2021; 16(3):e0247905.
    View in: PubMed
    Score: 0.048
  44. NRG Oncology/RTOG Consensus Guidelines for Delineation of Clinical Target Volume for Intensity Modulated Pelvic Radiation Therapy in Postoperative Treatment of Endometrial and Cervical Cancer: An Update. Int J Radiat Oncol Biol Phys. 2021 02 01; 109(2):413-424.
    View in: PubMed
    Score: 0.047
  45. A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation. Support Care Cancer. 2021 Jan; 29(1):213-222.
    View in: PubMed
    Score: 0.045
  46. Pelvic fractures and changes in bone mineral density after radiotherapy for cervical, endometrial, and vaginal cancer: A prospective study of 239 women. Cancer. 2020 06 01; 126(11):2607-2613.
    View in: PubMed
    Score: 0.045
  47. Quantifying institutional resource utilization of adjuvant brachytherapy and intensity-modulated radiation therapy for endometrial cancer via time-driven activity-based costing. Brachytherapy. 2019 Jul - Aug; 18(4):445-452.
    View in: PubMed
    Score: 0.042
  48. Patterns of recurrence and survival in neuroendocrine cervical cancer. Gynecol Oncol. 2016 Dec; 143(3):552-557.
    View in: PubMed
    Score: 0.035
  49. Isolated port-site metastases after minimally invasive hysterectomy for endometrial cancer: outcomes of patients treated with radiotherapy. Int J Gynecol Cancer. 2015 Jun; 25(5):869-74.
    View in: PubMed
    Score: 0.032
  50. Impact of heterogeneity-based dose calculation using a deterministic grid-based Boltzmann equation solver for intracavitary brachytherapy. Int J Radiat Oncol Biol Phys. 2012 Jul 01; 83(3):e417-22.
    View in: PubMed
    Score: 0.026
  51. Expression of nuclear transcription factor kappa B in locally advanced human cervical cancer treated with definitive chemoradiation. Int J Radiat Oncol Biol Phys. 2010 Dec 01; 78(5):1331-6.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.